Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.

"DISCLOSURE Sherko Kuemmel has received personal fees for consulting or advisory services from Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, PFM Medical, Pfizer, MSD Oncology, Lilly, Sonoscape, Gilead Sciences, Seagen, and Agendia; funding for travel and accommodation expenses from Roche, Daiichi Sankyo, and Sonoscape; and is Co-Director of the WSG Study group. Marc Thill has been a member of the Advisory Boards of Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Biom‘Up, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, PFM Medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Pintuition, and Sysmex; has received manuscript support from Amgen, ClearCut, Clovis, PFM Medical, Roche, and Servier; received funding for travel expenses from Amgen, Art Tempi, AstraZeneca, Clearcut, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, Hexal, I-Med-Institute, Lilly, MCI, Medtronic, MSD, Neodynamics, Norgine, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, and Seagen; received congress support from Amgen, AstraZeneca, Celgene, Daiichi Sanyko, Hexal, Neodynamics, Novartis, Pfizer, Roche, and Sirius Medical; received lecture honoraria from Amgen, Art Tempi, AstraZeneca, Clovis, Connect Medica, Eisai, Exact Sciences, Gedeon Richter, Gilead Science, GSK, Hexal, I-Med-Institute, Jörg Eickeler, Laborarztpraxis Walther et al., Lilly, MCI, Medscape, MSD, Medtronic, Novartis, Onkowissen, Pfizer, PFM Medical, Roche, Seagen, StreamedUp, Sysmex, Vifor, and Viatris; received trial funding from Endomag and Exact Sciences; and received trial honoraria from AstraZeneca, Biom’Up, Celgene, Clearcut, Neodynamics, Novartis, PFM Medical, Roche, and RTI Surgical. Marion van Mackelenbergh has received personal fees, honoraria, or travel grants from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, PierreFabre, Roche, and Seagen. Maggie Banys-Paluchowski has received honoraria for lectures and advisory boards from Roche, Novartis, Pfizer, PFM Medical, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, and ExactSciences; and has received study support from EndoMag, Mammotome, MeritMedical, Gilead, Hologic, and ExactSciences. Mattea Reinisch has received honoraria and/or consultancy fees and/or travel support from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, and Somatex. André Pfob, Lie Cai, Andreas Schneeweiss, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, Toralf Reimer, Markus Hahn, Jens-Uwe Blohmer, John Hackmann, Wolfram Malter, Inga Bekes, Kay Friedrichs, Sebastian Wojcinski, Sylvie Joos, Stefan Paepke, Tom Degenhardt, Joachim Rom, Achim Rody, Regina Große, Maria Margarete Karsten, Chris Sidey-Gibbons, Markus Wallwiener, Michael Golatta, and Joerg Heil have no conflicts of interest to declare in relation to this study."

"Funding Open Access funding enabled and organized by Projekt DEAL. This trial was funded by Deutsche Forschungsgemeinschaft (German Research Group, GZ:HE 6824/5-1). The funding body played no role in the study."